ABSTRACT
PURPOSE: Oral carbonic anhydrase inhibitors have been the treatment of choice for managing cystoid macular edema (CMO) in retinitis pigmentosa. We report a case illustrating the effectiveness of topical steroidal and nonsteroidal antiinflammatory drugs (NSAIDs) in managing CMO in a patient with retinitis pigmentosa, who is unable to take oral carbonic anhydrase inhibitor because of chronic renal impairment. METHODS: An 85-year-old woman with retinitis pigmentosa-related CMO in the left eye was prospectively followed up after treatment with a 4 times daily regimen consisting of a topical steroid (prednisolone acetate 1%) and an NSAID (ketorolac trometamol 0.5%). The right eye showed no evidence of CMO. Oral acetazolamide was avoided as the patient had chronic renal impairment. RESULTS: Three months after treatment, best-corrected visual acuity in the left eye improved from 20/200 to 20/60, and spectral domain optical coherence tomography showed complete resolution of CMO. Topical steroid and NSAID were therefore stopped. However, 6 months later, left best-corrected visual acuity was reduced to 20/120 and spectral domain optical coherence tomography showed recurrence of CMO. This was managed with the same treatment regimen of topical steroid and NSAID, which resulted in complete resolution of CMO with best-corrected visual acuity in the left eye improving to 20/80 after 3 months. CONCLUSION: To our knowledge, this is the first report that demonstrates the effectiveness of topical steroids or NSAIDs in managing CMO in a retinitis pigmentosa patient with chronic renal impairment who is unable to take a carbonic anhydrase inhibitor because of chronic renal impairment.
ABSTRACT
PURPOSE: Choroidal neovascular membranes (CNV) are the major cause of visual loss in punctate inner choroidopathy (PIC), an idiopathic inflammatory condition predominantly affecting young, myopic women. We present a case series of 9 patients with CNV associated with PIC, treated with intravitreal anti-vascular endothelial growth factor agents. METHODS: This is a retrospective case series of 9 patients treated with either intravitreal bevacizumab or ranibizumab for inflammatory CNV secondary to PIC. Initial and posttreatment converted logMAR visual acuity, fundus fluorescein angiograms (FFA), optical coherence tomography (OCT), previous and concurrent treatments, and side effects were recorded. Informed consent for treatment was obtained from each patient. RESULTS: Nine patients (8 female, 1 male) with an average age of 34.4 years were treated for an average of 14.9 months. Six patients were treated with bevacizumab, and 3 with ranibizumab, with a mean of 2.34 injections per year. The mean visual acuity gain for the whole group of 9 patients was 0.26 converted logMAR units (Wilcoxon signed-rank test, p<0.015). Eight patients remained stable or had visual improvement at final follow-up, with a mean gain of 0.36 converted logMAR units. Only one patient's vision deteriorated (loss of 0.48 converted logMAR units). Concomitant short courses of oral corticosteroid were used in 3 of the 9 patients. CONCLUSIONS: Over a 1-year period, bevacizumab and ranibizumab can be safely and successfully used to treat inflammatory CNV secondary to PIC, avoiding the need for systemic immunosuppression in the majority of patients.
Subject(s)
Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal, Humanized/administration & dosage , Choroidal Neovascularization/drug therapy , Uveitis, Posterior/complications , Visual Acuity/physiology , Adult , Bevacizumab , Choroidal Neovascularization/etiology , Choroidal Neovascularization/physiopathology , Female , Fluorescein Angiography , Follow-Up Studies , Humans , Intravitreal Injections , Male , Middle Aged , Ranibizumab , Retrospective Studies , Tomography, Optical Coherence , Treatment Outcome , Uveitis, Posterior/physiopathology , Vascular Endothelial Growth Factor A/antagonists & inhibitorsSubject(s)
Adrenergic alpha-Antagonists/adverse effects , Iris Diseases/chemically induced , Pupil/drug effects , Sulfonamides/adverse effects , Adrenergic alpha-1 Receptor Antagonists , Cataract Extraction , Humans , Intraoperative Complications , Iris Diseases/metabolism , Iris Diseases/prevention & control , Male , Muscle, Smooth/metabolism , Prostatic Hyperplasia/drug therapy , Receptors, Adrenergic, alpha-1/metabolism , Syndrome , TamsulosinABSTRACT
Anterior and posterior visual pathway disturbances have been reported post-coronary artery bypass graft surgery. Acute angle-closure glaucoma after general anaesthesia has also been well described in the literature. To date, however, there are only two cases of angle closure caused by tonic pupils. The case is reported herein of bilateral subacute angle-closure glaucoma that occurred following coronary artery bypass graft surgery in association with tonic pupils.